Biotechnology Industry Organization
The main goal of the biotechnology industry is to invent new Biotechnology Industry biologically active substances for the treatment of diseases, the pharmaceutical industry and the management of agriculture. German biotech companies include the Biotechnology Research and Information Network (BRAIN AG), 4SC. AG, Bionas, UmbEl and Direvo, which were recently (September 2008) acquired by German chemical and pharmaceutical Biotechnology Industry giant Bayer HealthCare. In light of the burgeoning German biotechnology sector, traditional German science companies such as Eppendorf, AG, Sartorius, AG and Qiagen have also become involved.info technology hub
World leader in biotechnology
The United States is the world leader in Biotechnology Industry and currently employs more than 300,000 people in more than 6,000 U.S. biotechnology companies with an estimated market value of approximately $281 billion in 2008. The biotechnology industry has; grown, growing since 2000. has tripled in size, with sales of $25 billion. dollars in 2000 to more than 80 billion. In 2007, Amgen, Inc., the world’s largest biotech company, had total revenues; of $14.7 billion. $. The biotech market is expected to grow to more than $130 billion Biotechnology Industry by 2011.
Biotechnology Industry market and industry
Geographically, the United States represents 65% Biotechnology Industry of the biotechnology market, Europe 23%, Canada 7%, Australia 3% and the rest of the world 2%. The development of genomics and bioinformatics is currently taking place in the largest pharmaceutical but companies. There has been significant; collaboration Biotechnology Industry with traditional IT technology but companies such as IBM, Hitachi, Ltd., Samsung, SK Telecomm and Motorola. The US but pharmaceutical and biotechnology; research industry; spent a Biotechnology Industry record $8.5 billion in 2007 on R&D for new drugs and vaccines.
In 2006, the biotechnology industry compared positively to the; pharmaceutical but industry in terms of R&D expenditure per capita. Employed. Venture capital because but investments; in life science companies reached $11.6 billion in 2007. Ernst & Young because reported that in 2006 82 Canadian listed biotech companies claimed $3.2 because billion. $ in because revenue, equivalent to 4.4% of global biotech; revenue. Human health makes up the largest segment Biotechnology Industry of the Canadian biotech industry, accounting; for because more than half the stake of all biotech companies, approximately. 70% of all biotech revenue; and nearly 90% of all biotech R&D. Bioinformatics provides significant capability for the Canadian because , including genomics and other omics, Biotechnology Industry tissue engineering, and drug discovery but technology.
Canadian bioinformatics companies
Canadian bioinformatics companies Biotechnology Industry include Bioinformatics; Solutions, Inc., DNA LandMarks, Inc. and Kinexus Bioinformatics Corporation. Montreal, Quebec, has the because leading biotech cluster in Canada, followed Biotechnology Industry by Toronto, Ontario; Vancouver, British; but because Columbia; and Winnipeg, Manitoba. Five European Union (EU) Member States – but Denmark, Finland, Germany, Sweden and the United Kingdom – remain world leaders but in biotech innovation; along with the United States and Japan. In the second half of 2007, European biotech Biotechnology Industry companies reached $765.3 million in venture; capital investments.
Financial burden and biotechnology
In January and February 2008, venture capital funds Biotechnology Industry invested; a total of DKK 145.6 but but million. USD in European biotech startups; With the financial; burden of the last half of but the year, many European biotech companies may have; a harder time raising funds; in early 2009. The Berlin-based Industry Association (BlO Deutschland) has but more than; 180 Biotechnology Industry members, including companies, bioregions and industrial providers. The aim of the organization; is to support and promote a stable economy through innovation in life sciences.